Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

experience the forgiveness of betrayal and effective factors

Abstract: Extramarital infidelity has serious consequences for relationship and the people involved. one of the way that help the betrayed person to control the effects of these consequences on himself and his relationship is forgiveness. In clinical setting, Forgiveness is used as therapeutic strategies to decrease the anger and emotional suffering from infidelity. If it is needed to use forg...

To What Extent Vital Signs Are Important to Medical Toxicologists When Conflicts Arise in Defining Toxidroms

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

A panel of leading Italian specialists in infectious diseases, virologists and immunologists met in Rome in 2005 to review critical data and discuss recommendations for each of the key questions in antiretroviral therapy today: When to start treatment? How to start? When to switch? What to switch to? Whether to stop or not to stop treatment, and how? The method of a nominal group meeting was us...

The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

BACKGROUND Guidelines for antiretroviral treatment (cART) are published regularly, but there is little information regarding the effect of adherence to guidelines on patient outcomes. We assessed the effect of following the "when-to-start" and "what-to-start" guidelines, on treatment modifications, and on immunological and virological outcome at 12 months in a cohort of HIV-1 infected patients ...